Multiple Skleroz

Kobelt G, Thompson A, Berg J, Gannedahl M, Eriksson J, Group MS, et al. New insights into the burden and costs of multiple sclerosis in Europe. Multiple Sclerosis Journal. 2017;23(8):1123-36.

McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and treatment of multiple sclerosis: a review. Jama. 2021;325(8):765-79.

Karussis D. The diagnosis of multiple sclerosis and the various related demyelinating syndromes: a critical review. Journal of autoimmunity. 2014;48:134-42.

Browne P, Chandraratna D, Angood C, Tremlett H, Baker C, Taylor BV, et al. Atlas of multiple sclerosis 2013: a growing global problem with widespread inequity. Neurology. 2014;83(11):1022-4.

Oh J, Vidal-Jordana A, Montalban X. Multiple sclerosis: clinical aspects. Current opinion in neurology. 2018;31(6):752-9.

Kingwell E, Marriott JJ, Jetté N, Pringsheim T, Makhani N, Morrow SA, et al. Incidence and prevalence of multiple sclerosis in Europe: a systematic review. BMC neurology. 2013;13(1):1-13.

Orton S-M, Herrera BM, Yee IM, Valdar W, Ramagopalan SV, Sadovnick AD, et al. Sex ratio of multiple sclerosis in Canada: a longitudinal study. The Lancet Neurology. 2006;5(11):932-6.

Dobson R, Giovannoni G. Multiple sclerosis–a review. European journal of neurology. 2019;26(1):27-40.

Efendi H. MULTİPL SKLEROZ TANI VE TEDAVİ KILAVUZU.

Nourbakhsh B, Mowry EM. Multiple sclerosis risk factors and pathogenesis. CONTINUUM: Lifelong Learning in Neurology. 2019;25(3):596-610.

Pearce J. Historical descriptions of multiple sclerosis. European neurology. 2005;54(1):49-53.

Neumann H, Medana IM, Bauer J, Lassmann H. Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trends in neurosciences. 2002;25(6):313-9.

Zarghami A, Li Y, Claflin SB, van der Mei I, Taylor BV. Role of environmental factors in multiple sclerosis. Expert Review of Neurotherapeutics. 2021;21(12):1389-408.

Consortium*† IMSG, ANZgene, IIBDGC, WTCCC2. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science. 2019;365(6460):eaav7188.

Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278-86.

Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. The Lancet Neurology. 2018;17(2):162-73.

Milo R, Miller A. Revised diagnostic criteria of multiple sclerosis. Autoimmunity reviews. 2014;13(4-5):518-24.

Hauser SL, Cree BA. Treatment of multiple sclerosis: a review. The American journal of medicine. 2020;133(12):1380-90. e2.

Mariotto S, Ferrari S, Monaco S, Benedetti MD, Schanda K, Alberti D, et al. Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study. Journal of neurology. 2017;264(12):2420-30.

O'Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, Olsson TP, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. New England Journal of Medicine. 2011;365(14):1293-303.

Manjunatha RT, Habib S, Sangaraju SL, Yepez D, Grandes XA. Multiple Sclerosis: Therapeutic Strategies on the Horizon. Cureus. 2022;14(5).

Kish T. Promising Multiple Sclerosis Agents In Late-Stage Development. Pharmacy and Therapeutics. 2018;43(12):750.

Oh J, Bar-Or A. Emerging therapies to target CNS pathophysiology in multiple sclerosis. Nature Reviews Neurology. 2022:1-10.

Piehl F. Current and emerging disease‐modulatory therapies and treatment targets for multiple sclerosis. Journal of internal medicine. 2021;289(6):771-91.